Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Decreases By 21.5%

Daré Bioscience, Inc. (NASDAQ:DARE) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 71,500 shares, a drop of 21.5% from the February 13th total of 91,100 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily volume of 36,300 shares, the short-interest ratio is presently 2.0 days.

Daré Bioscience Trading Up 2.3 %

NASDAQ:DARE traded up $0.07 during mid-day trading on Monday, reaching $2.95. 14,584 shares of the stock were exchanged, compared to its average volume of 45,982. Daré Bioscience has a 1-year low of $2.67 and a 1-year high of $7.56. The firm has a market capitalization of $25.62 million, a PE ratio of -4.99 and a beta of 1.38. The business has a fifty day moving average price of $3.15 and a 200 day moving average price of $3.33.

Hedge Funds Weigh In On Daré Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of DARE. Jane Street Group LLC acquired a new position in shares of Daré Bioscience in the 4th quarter valued at $52,000. Renaissance Technologies LLC raised its stake in shares of Daré Bioscience by 6.7% during the 4th quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 4,300 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Daré Bioscience by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after acquiring an additional 3,593 shares in the last quarter. Finally, AMH Equity Ltd raised its stake in shares of Daré Bioscience by 50.0% in the 4th quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 50,000 shares in the last quarter. Institutional investors and hedge funds own 6.70% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.